Xanthan Gum

1. INCI & CAS

INCI: Xanthan Gum · CAS: 11138-66-2

2. Role in the formula

Xanthan is the standard polysaccharide stabilizer. It is not a film drug.

3. Typical use levels (formulation guide)

• Emulsions: 0.15–0.4%

Pre-disperse in glycerin.

4. Regulatory sources & global compliance

• The CosIng record for Xanthan Gum, where listed, is informational rather than product-specific authorization.
• The framework in Regulation (EC) No 1223/2009 requires the complete cosmetic containing Xanthan Gum to receive its own safety assessment for the complete formula intended for sale.
• Match the selected Xanthan Gum material to its supplier TDS and check the filing list for the market of sale.

5. Safety & risk assessment

The listed use rate is intended as a cosmetic-development guide; it does not qualify a finished product as a drug or OTC product and patch and stability testing remain part of finished-product review.

6. Stability & packaging

Use cool, sealed storage away from strong light for the bulk; match the pack choice to the system's oxidation risk; check the finished batch's stability and package compatibility.

7. Claims language (Do / Don’t)

• Supports an emulsion-stabilizer story

• This reference is not evidence of therapeutic effects, curative outcomes, or unsupported certification statements.
• The formulation record for Xanthan Gum cannot establish whitening effects, acne treatment, antiperspirant performance, sunscreen protection, or hair growth.

1. INCI & CAS

INCI: Glycerin · CAS: 56-81-5

2. Role in the formula

Glycerin serves as the polyol humectant in these cosmetic formats, while the stated percentage remains a formulation reference.

3. Typical use levels (formulation guide)

• Formulation guidance for gels and serums: 3–8%.
• For creams, the reference gives 2–5%.
• Formulation guidance for rinse-off: 2–4% as a formulation guide.

The water phase is the addition point for Glycerin; a separate melt is unnecessary.

4. Regulatory sources & global compliance

• Use CosIng's information on Glycerin as a reference, then verify the specific grade and intended use under market rules.
• The finished-product provisions of Regulation (EC) No 1223/2009 require the final cosmetic with Glycerin to undergo a safety assessment for the specific product as it will be marketed.
• Establish grade-specific details for Glycerin from the supplier and assess filing requirements in the intended market.

5. Safety & risk assessment

Use the stated level as reference guidance for cosmetic formulation; no drug approval or OTC status is conferred by this entry with patch response and finished-product stability still to be verified.

6. Stability & packaging

Store sealed bulk away from heat and sunlight; where appropriate, assess an airless or pump pack for oxidation-sensitive systems; then verify formula stability and pack compatibility on the confirmed batch.

7. Claims language (Do / Don’t)

• This guide frames Glycerin's cosmetic direction around humectant function.

• The listed information does not demonstrate claims of drug activity, a clinical cure, or an undocumented product certification.
• The documented facts for Glycerin does not demonstrate whitening, acne treatment, antiperspirant effects, sunscreen use, or hair growth.

1. INCI & CAS

INCI: Squalane · CAS: 111-01-3

2. Role in the formula

The guide uses plant-derived squalane, a stable hydrocarbon emollient, and does not specify mineral oil.

3. Typical use levels (formulation guide)

• For gel-creams, the reference gives 2–6% in this reference.
• For dry oils, the reference gives 10–30% as a formulation guide.
• The stated reference for balms is 5–15% for the formula.

Add Squalane to the oil phase; no high-shear wax step is required.

4. Regulatory sources & global compliance

• CosIng information about Squalane does not itself authorize a particular grade or finished cosmetic.
• The EU Cosmetics Regulation (EC) No 1223/2009 requires the complete cosmetic containing Squalane to receive its own safety assessment before release of the finished cosmetic.
• Compare the received Squalane material with its supplier specification and review destination-market filing needs.

5. Safety & risk assessment

The listed use rate is intended as a cosmetic-development guide; it is not evidence of drug approval or OTC authorization so assess patch response and stability in the final formula.

6. Stability & packaging

Store the bulk in a closed container in a cool, shaded place; if oxidation risk calls for it, review a pump or airless format; then verify formula stability and pack compatibility on the confirmed batch.

7. Claims language (Do / Don’t)

• The listed cosmetic direction for Squalane emphasizes a light-emollient role.

• The available ingredient details does not demonstrate drug or therapeutic claims, clinical cures, or certification claims not confirmed for the product.
• The ingredient record for Squalane offers no support for whitening, treatment of acne, perspiration control, sun protection, or hair growth.